Key Takeaways EDIT advances CRISPR-based EDIT-401, showing over 90% LDL-C reduction in preclinical tests.SANA pushes ex vivo and in vivo platforms, with IND plans for SC451 in 2026 and SG293 in 2027.PACB delivers advanced long-read sequencing tools serving research, clinical and commercial users.An updated edition of the Sept. 18, 2025, article.Genomics is a comprehensive study of genomes (an organism’s complete set of deoxyribonucleic acid or DNA). Given the recent promising breakthroughs in this field, th ...

Core Insights - Artisan Partners' "Artisan Small Cap Fund" reported strong performance in Q3 2025, with major US indices reaching record highs and the fund's Investor Class returning 8.69% [1] - Twist Bioscience Corporation (NASDAQ:TWST) was highlighted as a detractor in the fund's performance, with a one-month return of -20.34% and a 52-week loss of 37.05% [2][3] Fund Performance - The Artisan Small Cap Fund's Advisor Class fund returned 8.75%, and the Institutional Class fund returned 8.73%, while the Russell 2000 Growth Index returned 12.19% [1] - The fund's top 5 holdings were mentioned as key picks for 2025 [1] Company Analysis: Twist Bioscience Corporation - Twist Bioscience reported 18% revenue growth, driven by demand in next-generation sequencing, despite weaker sales in synthetic biology products [3] - The company has a market capitalization of $1.58 billion, with shares closing at $26.87 on November 14, 2025 [2] - The partnership with Veracyte is viewed as a validation of Twist's platform, potentially driving long-term upside [3] Hedge Fund Interest - Twist Bioscience was held by 23 hedge fund portfolios at the end of Q2 2025, a decrease from 30 in the previous quarter [4] - The company reported revenue of $99 million in Q4 2025, reflecting a 17% year-over-year growth [4]

Core Insights - Ginkgo Bioworks has been awarded a contract valued at up to $22.2 million by BARDA to develop innovations for the biomanufacturing of monoclonal antibodies (mAbs) aimed at combating filoviruses like Ebola and Sudan viruses [2][4] Group 1: Project Overview - The project aims to produce an anti-filovirus mAbs cocktail, specifically 1C3 and 1C11, which were discovered and developed by Emory University [2] - Ginkgo will lead a consortium that includes Advanced BioScience Laboratories (ABL), Isolere Bio by Donaldson, NeuImmune, Inc., and ProteoNic BV to enhance the entire mAb production process [2][3] Group 2: Importance and Goals - The initiative is crucial for national biosecurity and public health preparedness, emphasizing the need for rapidly scalable and cost-effective mAb manufacturing [3] - The collaboration aims to protect the U.S. population from high-threat pathogens, with a focus on developing effective medical countermeasures against filoviral infections [3] Group 3: Partner Contributions - ABL will provide product production capabilities, aiming to redefine efficacy standards against infectious diseases [3] - Isolere Bio by Donaldson will contribute to bioprocessing solutions that enhance efficiency and reduce costs for essential medicines [3] - NeuImmune will leverage its proprietary geCHO BioDesign platform to advance novel antibodies for treating filoviral infections [3] - ProteoNic will utilize its 2G UNic® vector technology to develop an efficient production process for the mAbs [3] Group 4: Background and Funding - This project builds on Ginkgo Bioworks' history of collaboration with the U.S. government in synthetic biology and biomanufacturing innovation [4] - The funding for this initiative comes from federal sources, specifically the U.S. Department of Health and Human Services and BARDA [4]

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the 2025 ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York City. CEO of eXoZymes, Michael Heltzen, states, "Most investors already know that - compared to the number of ...

Core Viewpoint - The Guangzhou Frontier Biotechnology and Biomanufacturing Innovation Promotion Center was inaugurated to support the development of the biomanufacturing industry in Guangzhou, focusing on technology supply, innovation transformation, and talent cultivation [1][2][4]. Group 1: Innovation Center Overview - The Innovation Center is a collaborative initiative led by Sun Yat-sen University, involving local universities, research institutions, and key enterprises, aimed at establishing a new innovation ecosystem for biomanufacturing [2][4]. - The center will adopt a model of "1 headquarters (Sun Yat-sen University) + M innovation platforms (such as strain libraries and pilot testing centers) + N application scenarios," facilitating various biomanufacturing applications [4]. Group 2: Strategic Focus Areas - The center will concentrate on key technological breakthroughs in synthetic biology and biomanufacturing, integrating resources from government, industry, academia, and finance to create a comprehensive innovation chain [4][5]. - Guangzhou aims to develop a competitive biomanufacturing industry cluster by 2027, focusing on five key areas: biomedicine, biomaterials, biofood, biohealth, and bioagriculture [5][6]. Group 3: Industry Foundation and Future Plans - The city has established a strong foundation for the biomanufacturing industry, with several core technology enterprises and robust research institutions [6][8]. - The Guangzhou government plans to introduce policies to support the biomanufacturing sector, emphasizing the importance of market demand for industry growth [8].

Summary of Scientific Industries Conference Call Company Overview - **Company Name**: Scientific Industries - **Ticker**: SCND - **Industry**: Scientific Instruments, Life Sciences - **Transformation**: Focused on digitally simplifying science, particularly in life sciences over the last five years [2][3] Key Points and Arguments Financial Performance and Strategy - **Historical Success**: The company was profitable and paid dividends before the transformation [2] - **Acquisitions**: - Acquired Fluorimetrics for $450,000, generating nearly $9 million in gross royalties [3] - Sold the Genie business to Mettler Toledo for $11 million, strengthening the balance sheet with no debt [3][20] - **Current Financials**: - Approximately $30 million raised for new product lines [3] - $10 million in cash and milestone payments from the Genie transaction [5] - Market cap around $7 million, indicating significant investment relative to market value [5] Product Development and Market Opportunities - **Torbal**: - Focus on pharmacy automation with a growing product line [4] - Targeting a market of 20,000 independent pharmacies and 48,000 chain and hospital pharmacies [6] - Introduction of a machine learning pill recognition system, enhancing competitive advantage [7][8] - **Scientific Bioprocessing**: - Fast-growing business in synthetic biology and personal gene therapy technology [4] - Addressing a $2 billion market in biomanufacturing with the DOTS platform [9] - Aiming for $20 million in sales and 20% EBITDA by 2029 [10] Technological Innovations - **DOTS Platform**: - Reduces experiment costs from $10,000 to $200, significantly improving ROI for customers [13][14] - Enables real-time data collection and AI integration for better decision-making [15][17] - **AI Integration**: - Positioning as a key player in the synthetic biology revolution, likening the product to the iPhone of the industry [22] Market Position and Future Outlook - **Customer Base**: - Established relationships with major life sciences companies like Pfizer and Amgen [18] - Positive ROI demonstrated by customers, such as Bond Pet Foods achieving a $70,000 savings from a $55,000 investment [19] - **Future Goals**: - Focus on product development and meeting deadlines for the bioprocessing business in 2025 [30] - Continued investment in the Vivid product line to enhance pharmacy automation [31] Additional Important Insights - **Regulatory Environment**: - Federal regulations like Track and Trace are driving demand for automated pharmacy tools [6] - **Cloud-Based Solutions**: - Vivid's cloud architecture enhances scalability, security, and compliance in pharmacy environments [28][29] - **Market Trends**: - The aging population is creating a demand for pharmacy automation due to a shortage of pharmacists [4] This summary encapsulates the key points discussed during the conference call, highlighting the strategic direction, financial health, product innovations, and market opportunities for Scientific Industries.

Core Technology & Scientific Advancements - The industry is at the cusp of programming life by understanding and manipulating cells like sophisticated software [5][6] - Systems biology offers a holistic approach to reprogramming life by mapping molecular interactions within cells, similar to a city-wide traffic map, to identify bottlenecks in disease networks [7][8] - Genetically Encoded Metabolic Manipulators and Sensors (GEMS) are DNA-based living therapies that act as molecular smoke detectors to restore balance in cancer cells [13] - Synthetic biology tools, like CRISPR, enable modular design of living therapies, allowing for rapid updates and adaptive defense strategies against diseases [14] Applications & Bioeconomy - Synthetic biology can be applied to create sustainable biofactories for producing fuels, food flavors, and materials from renewable resources, reducing reliance on fossil fuels and carbon emissions [19] - Microbial strains can be engineered to produce valuable compounds like violacein (a purple pigment with antimicrobial properties) and vanillin (vanilla flavor), as well as biodegradable plastics [20][21] - Synthetic biology is rewriting product design and rebuilding global supply chains, potentially impacting various industries from toothpaste to pharmaceuticals [23] Ethical Considerations & Future Implications - Advances in genetic engineering raise ethical questions about genetic personalization, designer babies, and the potential for exacerbating social inequalities [25] - The industry emphasizes the need for public awareness, open dialogue, and responsible governance to navigate the ethical implications of programming life [26] - The industry is at the dawn of a biological renaissance, with DNA as the code and humanity as the storytellers, holding the power to program life itself [28]

Industry Overview - Genomics is a comprehensive study of genomes, focusing on understanding gene functions and interactions within organisms and their environments [1][2] - The field of genomics is gaining traction among pharmaceutical and biotechnology companies due to recent breakthroughs and the potential for personalized medicine [2][4] Market Potential - The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market was valued at $16.2 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [7] Key Companies GeneDx Holdings Corp. - GeneDx is a leading genomics company specializing in exome and genome tests, which surged 69% year-over-year to $85.9 million in Q2 2025, with test volume increasing by 28% [10] - The company acquired Fabric Genomics in May 2025 to enhance genomic diagnostics through AI-powered interpretation services [11][12] - GeneDx currently holds a Zacks Rank 1 (Strong Buy) [12] Twist Biosciences - Twist Biosciences has developed a DNA synthesis platform for engineering biology, producing synthetic DNA products for various applications, including drug discovery [13][14] - The company has expanded its offerings to include synthetic RNA and antibody proteins, catering to biotech, pharma, and industrial sectors [14][15] - Twist Biosciences holds a Zacks Rank 3 (Hold) [15] Wave Life Sciences - Wave Life Sciences focuses on RNA medicines, utilizing its PRISM platform to develop treatments for both rare and common disorders [16] - The company has a diverse pipeline targeting conditions such as obesity, AATD, DMD, and HD, with its first siRNA candidate, WVE-007, entering clinical development [17][18] - Wave Life Sciences ended Q2 with cash and equivalents of $208.5 million, sufficient to fund operations into 2027, and holds a Zacks Rank 3 [19]

Core Insights - Twist Bioscience Corp. (NASDAQ:TWST) is recognized as a leading emerging technology stock, specializing in synthetic DNA manufacturing through a silicon-based synthesis platform, which offers scalable production with high accuracy and affordability compared to traditional methods [1][6] Company Performance - TD Cowen analyst Brendan Smith reaffirmed a Buy rating on Twist Bioscience with a price target of $36 following the company's presentation at the Baird Global Healthcare Conference 2025, where management discussed advancements in profitability and operational efficiency [3] - The company reported gross margins exceeding 50%, indicating effective scaling and disciplined execution, with a goal to achieve adjusted EBITDA breakeven by fiscal 2026 [4] - Management noted that each additional dollar of revenue contributes approximately $0.75 to $0.80 to gross margin [4] Growth Opportunities - Management identified several growth levers, including the expansion of the MRD opportunity, customer migration from microarrays to Twist's sequencing solutions, and further integration of synthetic biology with biopharma [5] - Despite the growth potential, challenges such as a tough funding environment and the need to balance cost discipline with innovation were acknowledged [5] Industry Context - The platform developed by Twist Bioscience has applications in various sectors, including drug discovery, diagnostics, agriculture, and data storage, positioning the company as a frontrunner in the commercial potential of synthetic biology [2]

🐺MUST SEE: Charles Hoskinson plans to bring back the DIRE WOLF using synthetic biology.“You can take a gray wolf and an extinct dire wolf, put them together, and get your peanut butter and jelly wolf, your dire wolf.” https://t.co/AeR2bQNPTg ...